The Mechanistic Target of Rapamycin (mTOR) Pathway as a Target of Anti-aging Therapies: The Role of Rapamycin and Its Analogs in the Regulation of Cellular Processes and Their Impact on Longevity - Cureus
mTOR inhibition is extending healthspan in clinical settings,
Cureus Journal of Medical Science has emerged as a transformative platform in medical research publishing, offering a streamlined and cost-effective alternative to traditional journals. Backed by Springer Nature, Cureus emphasizes accessibility, allowing researchers to publish their work with minimal financial barriers—often at a fraction of the cost typical in the industry.
This innovative approach is particularly significant for the longevity and healthspan research community, where timely dissemination of findings can accelerate advancements in therapeutics and clinical applications. With an Impact Factor of 1.3 and over 165,000 citations, Cureus is fostering collaboration and engagement among researchers worldwide, promoting a more inclusive environment for sharing vital medical knowledge.
For professionals in aging biology and related fields, Cureus represents an opportunity to contribute to a rapidly evolving discourse while ensuring their research reaches a broader audience. I encourage you to explore the full details about publishing with Cureus and its impact on the future of medical research.